LTRN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Lantern Pharma receives USPTO Notice of Allowance for an LP-284 treatment patent targeting aggressive B-cell lymphomasSep 22, 2026
- Lantern Pharma will present its Open-Medicine AI multi-agent platform, business model, roadmap, and value proposition on September 23Sep 17, 2026
- Lantern Pharma advances EMA-cleared Phase 1b/2 trial of LP-184 in biomarker-selected advanced bladder cancerJul 28, 2026
- Lantern Pharma receives a USPTO notice of allowance for a patent covering biomarker-guided LP-184 treatment in multiple solid tumorsJul 23, 2026
- Lantern Pharma launched ZetaOmics, an AI-powered computational biologist for cancer researchJul 8, 2026